Shield Therapeutics plc
("Shield" or the "Company" or the "Group")
Block Listing 6 Monthly Return
|
Name of applicant: |
SHIELD THERAPEUTICS PLC |
|||
|
Name of scheme: |
Shield Therapeutics Retention Share Plan |
|||
|
Period of return: |
From: |
30 September 2022 |
To: |
31 March 2023 |
|
Balance of unallotted securities under scheme(s) from previous return: |
39,794 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
39,794 |
|||
|
Name of applicant: |
SHIELD THERAPEUTICS PLC |
|||
|
Name of scheme: |
Shield Therapeutics plc 2016 Company Share Option Plan |
|||
|
Period of return: |
From: |
30 September 2022 |
To: |
31 March 2023 |
|
Balance of unallotted securities under scheme(s) from previous return: |
341,020 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
341,020 |
|||
|
Name of applicant: |
SHIELD THERAPEUTICS PLC |
|||
|
Name of scheme: |
The Shield Therapeutics plc 2016 Long Term Incentive Plan |
|||
|
Period of return: |
From: |
30 September 2022 |
To: |
31 March 2023 |
|
Balance of unallotted securities under scheme(s) from previous return: |
24,273 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
NIL |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
24,273 |
|||
|
Name of applicant: |
SHIELD THERAPEUTICS PLC |
|||
|
Name of scheme: |
Shield Therapeutics Retention and Performance Share Plan |
|||
|
Period of return: |
From: |
30 September 2022 |
To: |
31 March 2023 |
|
Balance of unallotted securities under scheme(s) from previous return: |
4,870,838 |
|||
|
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): |
NIL |
|||
|
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): |
2,000,000 |
|||
|
Equals: Balance under scheme(s) not yet issued/allotted at end of period: |
2,870,838 |
|||
|
Name of contact: |
Lucy Huntington-Bailey |
|
Telephone number of contact: |
+44 (0) 191 511 8500 |
For further information please contact:
|
Shield Therapeutics plc |
|
|
Greg Madison, CEO |
+44 (0) 191 511 8500 |
|
Hans-Peter Rudolf, CFO |
|
|
Nominated Adviser and Joint Broker |
|
|
Peel Hunt LLP |
|
|
James Steel/Oliver Duckworth |
+44 (0)20 7418 8900 |
|
Joint Broker finnCap Ltd Geoff Nash/ George Dollemore/Alice Lane/Nigel Birks |
+44 (0)20 7220 0500 |
|
Financial PR & IR Advisor |
|
|
Walbrook PR |
|
|
Lianne Applegarth/Alice Woodings |
+44 (0)20 7933 8780 or shield@walbrookpr.com |
|
Investor Contact (US Advisor) LifeSci Advisors, LLC John Mullaly |
+1 617 429 3548 or jmullaly@lifesciadvisors.com |
About Accrufer®/Feraccru®
Accrufer®/Feraccru® (ferric maltol) is a novel, stable, non-salt based oral therapy for adults with iron deficiency, with or without anemia. Accrufer®/Feraccru® has a novel mechanism of action compared to other oral iron therapies and has been shown to be an efficacious and well-tolerated therapy in a range of clinical trials. More information about Accrufer®/Feraccru®, including the product label, can be found at: www.accrufer.com and www.feraccru.com
About Shield Therapeutics plc
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group